• Daniela M Menichella, Nirupa D Jayaraj, Heather M Wilson, Dongjun Ren, Kelsey Flood, Xiao-Qi Wang, Andrew Shum, Richard J Miller, and Amy S Paller.
• Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA d-menichella@northwestern.edu apaller@northwestern.edu.
• Mol Pain. 2016 Jan 1; 12.

BackgroundSmall fiber neuropathy is a well-recognized complication of type 2 diabetes and has been shown to be responsible for both neuropathic pain and impaired wound healing. In previous studies, we have demonstrated that ganglioside GM3 depletion by knockdown of GM3 synthase fully reverses impaired wound healing in diabetic mice. However, the role of GM3 in neuropathic pain and small fiber neuropathy in diabetes is unknown.PurposeDetermine whether GM3 depletion is able to reverse neuropathic pain and small fibers neuropathy and the mechanism of the reversal.ResultsWe demonstrate that GM3 synthase knockout and the resultant GM3 depletion rescues the denervation in mouse footpad skin and fully reverses the neuropathic pain in diet-induced obese diabetic mice. In cultured dorsal root ganglia from diet-induced diabetic mice, GM3 depletion protects against increased intracellular calcium influx in vitro.ConclusionsThese studies establish ganglioside GM3 as a new candidate responsible for neuropathic pain and small fiber neuropathy in diabetes. Moreover, these observations indicate that systemic or topically applied interventions aimed at depleting GM3 may improve both the painful neuropathy and the wound healing impairment in diabetes by protecting against nerve end terminal degeneration, providing a disease-modifying approach to this common, currently intractable medical issue.© The Author(s) 2016.

53 keywords...

hide…